Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04113278

Enrollment

Registered

2019-10-02

Start date

2019-11-01

Completion date

2021-09-01

Last updated

2019-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor Adult

Brief summary

The study population was selected from high grade glioma pateints attending the Department of Clinical Oncology, Assiut University hospital during the period from December 2018 to September 2020, we analyzed human high grade gliomas paraffin block for FLG2 expression

Detailed description

Glioblastoma is the most common malignant primary brain tumor in adults, and despite aggressive treatment, it is incurable Patient prognosis differs considerably within the different World Health Organization (WHO) grades, poorest prognosis for patients with the grade IV tumour- the glioblastoma multiform (GBM). Fibrinogen-like protein 2 (FGL2),regulates both innate and adaptive immunity. FGL2 is a 439 amino acid secreted protein that is similar to the β- and γ-chains of fibrinogen. Secreted FGL2 (sFGL2) is the key regulator in immunosuppression may play important role in malignant transformation of low to high by inhibiting the proliferation of T cell Study the role of fibrinogen-like protein2 on Immunosuppression and progression ，free survival and overall survival in high grade glioma

Interventions

GENETICFGL2 immunohisyochemistry

Correlation between FLG2 expression and progression free survival and overall surviv

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Inclusion criteria

* Pateints\>18 years old * Pathologically proven high grade glioma * Total or subtotal resection of the tumor * Patients received concurrent radiation therapy with temozolomide followed by adjuvant temozolamide for 6 months

Exclusion criteria

* Pregnancy * Breast feeding * Other comorbidity * Previous malignancy or radiation therapy or chemotherapy

Design outcomes

Primary

Measure	Time frame	Description
Rple of FGL2in high grade glioma as aprognostic factor	baseline	Correlation between FLG2 expression and progression free survival and overall survival

Contacts

Primary Contactsamir shehata, professor

Samir-eid@Hotmail.com01222302375

Backup Contactmohammed alaa, professor

m.alaa200@hotmail.com01005085973

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026